Recombinant human deoxyribonuclease I (rhDNase) is a new therapeutic agent developed to improve clearance of purulent sputum from the human airways. It is delivered by inhalation. Four jet nebulizers, T Up-Draft II (Hudson), Customized Respirgard II (Marquest), Acorn II (Marquest), and Airlife Misty (Baxter), were evaluated in vitro for their ability to deliver aerosols of rhDNase. The aerosols were generated from 2.5-mL aqueous solutions of rhDNase, at concentrations of either 1 or 4 mg/mL. In all experiments, the Pulmo-Aide Compressor (De Vilbiss) was used to supply the air to the nebulizers. Between 20 and 28% of the rhDNase dose initially placed in the nebulizers was delivered to the mouthpiece in the respirable range (1-6 microns). Evaluation of the rhDNase following nebulization in all four devices indicated that there was no loss in enzymatic activity and no increase in aggregation. Circular dichroism spectrophotometry indicated there was no change in either the secondary or the tertiary structure in rhDNase following nebulization. These results show that all four nebulizers are essentially equivalent in their ability to deliver respirable doses of rhDNase in an intact, fully active form. Changing the concentration of the solution in the nebulizer from 4 to 1 mg/mL rhDNase leads to a proportional reduction in the respirable dose delivered to the mouthpiece.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1018998028490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrapleural fibrinolytic therapy for pleural infections: Outcomes from a cohort study.
Ann Acad Med Singap
December 2024
Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Introduction: Pleural infections are a significant cause of mortality. Intrapleural fibrinolytic therapy (IPFT) utilising alteplase and dornase is a treatment option for patients unsuitable for surgery. The optimal dose of alteplase is unknown, and factors affecting treatment success in an Asian population are unclear.
View Article and Find Full Text PDFPatterns of Use of β-2 Agonists, Steroids, and Mucoactive Medications to Treat Bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study.
Pediatr Crit Care Med
December 2024
Department of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT.
Objectives: Describe β2-agonists, steroids, hypertonic saline (HTS), n-acetylcysteine (NAC), and dornase alfa (DA) use to treat bronchiolitis, factors associated with use, and associations between use and PICU length of stay (LOS).
Design: Retrospective, multicenter cohort study.
Setting: PICUs in the Pediatric Health Information System database.
Streptococcus constellatus Empyema: A Case Highlighting the Need for Timely Surgical Intervention.
Cureus
October 2024
Internal Medicine, Norton Community Hospital, Norton, USA.
This case report explores the intricate challenges of diagnosing and managing empyema caused by , particularly in patients with predisposing factors such as alcohol abuse and underlying respiratory conditions. We present a 34-year-old male patient with a medical history of hypertension, peripheral neuropathy, and alcohol abuse who developed empyema. Despite an initial presentation at another facility with symptoms mimicking a myocardial infarction and unremarkable chest X-ray results, his condition worsened, leading to a subsequent emergency department visit.
View Article and Find Full Text PDFProcess and validity of linking cystic fibrosis patient registry with national Medicaid databases.
J Cyst Fibros
November 2024
Rutgers University Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, USA; Department of Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA. Electronic address:
Article Synopsis
- * A matching algorithm was used to connect 10,616 individuals with CF from CFFPR to Medicaid data, revealing that those linked had significantly higher outpatient visits and antibiotic prescriptions than reported in the CFFPR alone.
- * The study found high costs associated with CF treatment in North Carolina, with pharmacy costs reaching $16.4 million and non-pharmacy costs totaling $7.5 million, highlighting the potential for comprehensive analysis of healthcare utilization and costs for low-income CF patients through linked data.
Novel management of pseudomonas biofilm-like structure in a post-pneumonectomy empyema.
Front Cell Infect Microbiol
November 2024
National Institutes of Health, National Cancer Institute, Thoracic Surgery Branch, Bethesda, MD, United States.
We present a patient with a post-pneumonectomy empyema refractory to surgical debridement and systemic antibiotics. The patient initially presented with a bronchopleural fistula and pneumothorax secondary to tuberculosis (TB) destroyed lung, which required a pneumonectomy with Eloesser flap. Ongoing pleural infection delayed the closure of the Eloesser flap, and thoracoscopic inspection of his chest cavity revealed a green, mucous biofilm-like structure lining the postpneumonectomy pleural cavity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!